Trial Profile
Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 06 Jul 2012 Actual end date (May 2008) added as reported by German Clinical Trials Register record.
- 25 Aug 2011 New source identified and integrated (German Clinical Trials Register record DRKS00000600).
- 08 Dec 2008 Status changed from active, no longer recruiting to completed.